This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: ARROS-1 Study - Zidesamtinib in Advanced ROS1 Fusion-Positive NSCLC and Other Solid Tumors

37 views
October 1, 2024
Comments 0
Login to view comments. Click here to Login